BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Account Payables
Amounts the company owes suppliers for goods and services received.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 231.0% from a year ago
Account payables stood at $12.09M at the end of Q1 FY2026, up 231.0% from a year earlier and up 779.9% from the prior quarter.
Context
- Account payables amounted to 2.9% of total assets at the end of Q1 FY2026, up 0.5 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +231.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 1.37M USD
- Year-over-year change
- —
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.37M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Account Payables vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +231.0% is the 2nd highest of 10, against a peer median of +18.1%.
- Account payables amounts to 2.9% of total assets for BBOT, versus a peer median of 2.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Aug 2026 | $32.98M USD | +283.1% | +30.3% | 2.8% | |
| Mar 2026 | $17.21M USD | +18.1% | +30.0% | 6.8% | |
| Sep 2026 | $16.86M USD | +62.5% | +12.1% | 8.1% | |
| Jun 2026 | $12.65M USD | -31.8% | +2.4% | 1.7% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $12.09M USD | +231.0% | — | 2.9% |
| Mar 2026 | $7.52M USD | +22.8% | +11.6% | 2.3% | |
SEPNSepterna, Inc. | Sep 2026 | $6.96M USD | +86.7% | +49.6% | 1.1% |
| Mar 2026 | $6.37M USD | -45.2% | -20.7% | 2.1% | |
| Mar 2026 | CHF 4.48M CHF | +3.0% | -22.5% | 1.8% | |
| Sep 2026 | $1.65M USD | -26.0% | -35.7% | 0.2% | |
| Peer median (excluding BBOT) | — | +18.1% | +11.6% | 2.1% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.